Amicus Therapeutics Inc (NASDAQ: FOLD). Significant negative changes in fundamentals have recently occurred: the stock’s power rating fell below 50, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Amicus Therapeutics Inc (NASDAQ: FOLD). Extremely important negative changes in investment behavior have recently occurred: negative upside/downside volume developed, and its shorter term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, FOLD is expected to be an important Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Amicus Therapeutics has a slightly negative Power Rating of 38 and a very low Appreciation Score of 1, triggering the Lowest Value Trend Rating.
Recent Price Action
Amicus Therapeutics Inc (NASDAQ: FOLD) stock closed at $12.30 on 3/8/24 after a slight gain of 0.08%. Moreover, trading volume in this advance was above average at 132% of normal. The stock has declined -4.1% during the last week and has performed in line with the market over the last nine months.
Be the first to comment